The Mondial Diagnostics Team
René Paulussen - Managing Director
René has more than 30 years of experience in the pharmaceutical/biotechnology/diagnostics domain, from the laboratory bench to senior management roles. He received his PhD in biochemistry from the University of Nijmegen, the Netherlands. While at the State Institute for Quality Control of Agricultural Products (RIKILT) he also worked part-time at the EU Bureau Communautaire de Reference where he was involved in harmonization of laboratory testing quality management across Europe. At pharmaceutical company Organon he headed the immunochemistry and cell-based assay activities, and held responsibilities for the implementation of a Laboratory Information Management System and for outsourcing of bioanalysis work to (inter)national CROs. Through the latter contacts he made a transition to Phoenix International Life Sciences to head up the ligand-binding assay services department in Montreal, Canada where he is now living for more than 20 years. After a short stint at startup biotech Xanthus Life Sciences, in 2002 René became Chief Operating Officer of Genizon BioSciences, a genetic and pharmacogenomics research company. After Genizon he spent several years in the field of biological sample management before joining Mondial Diagnostics as Managing Director in 2016. Throughout his career René developed extensive experience in R&D management, business planning, budgeting and finance. He combines his expertise in biomarkers, laboratory assays, and quality management with a strong track record of building multidisciplinary teams with a problem-solving attitude. René is a board member of Tillia Pharma, a company targeting the treatment and diagnosis of tropical skin diseases. Next to his professional activities René is involved with the Pure Art Foundation, a registered Canadian charitable organization bringing shelter, education and first-line healthcare to marginalized communities in the developing world. He continues to expand his language skills (Dutch, English, French, German, and Spanish) and enjoys playing Latin percussion.
Erika van den Bogaart - Senior Laboratory Scientist
Erika van den Bogaart obtained an MSc degree in Medicinal Chemistry and Technology from the University of Milan, Italy, and is a licensed pharmacist. During her studies she developed a special interest in tropical infectious diseases, and in 2008, on a fellowship, she joined the Parasitology Group at the Biomedical Research division of the Royal Tropical Institute (KIT-BR) in Amsterdam, The Netherlands, where she conducted extensive research in the field of antiprotozoal drug discovery. In 2012, she became a member of the KIT-BR Rapid Diagnostics Group, and began working on the development and evaluation of simple diagnostic tests for infectious diseases. In parallel she pursued her PhD studies on the epidemiological and immunological characterization of visceral leishmaniasis–malaria coinfections, and obtained her doctorate in early 2017 from the University of Amsterdam. She has been involved in multiple national and international research projects focusing on therapeutic and diagnostic solutions for tropical infectious diseases, and supervised several MSc and undergraduate students. At Mondial Diagnostics Erika is responsible for the development of point-of-care diagnostics tests for poverty-related diseases and the application of novel technology platforms for diagnostic assays.
Theresia Abdoel - Senior Development Specialist
Theresia is an experienced research technician specialized in the development and evaluation of diagnostics. She obtained her BASc in microbiology at the Hogeschool Eindhoven in 1998 and since then has gained extensive experience in the development of rapid diagnostics assays such as the lateral flow and latex based agglutination assays. She developed several diagnostic tests, including lateral flow assays for the detection of leptospirosis and brucellosis for human and veterinary use, and has worked on the development of a simple diagnostic tool for simultaneous diagnosis of HIV and syphilis infections in pregnant women. Theresia has extensive knowledge and experience with a variety of laboratory techniques such as ELISA, cell culture, molecular cloning, protein expression and purification, and is well versed in quality management systems and documentation (SOPs). She is also trained as an internal auditor.
Board of Directors
Joost Ruitenberg - Chairman
Joost Ruitenberg DVM PhD, Immunologist, Professor International Public Health VU University Amsterdam, emeritus Professor of Immunology Utrecht University. Previously Joost was the General and Scientific Director of the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (now Sanquin), Amsterdam and Deputy Director General of the National Institute of Public Health and Environment, Bilthoven.He is Chairman of the Aglaia Oncology Fund, the Nutricia Research Foundation and the Nelly Reef Fund, and previously served as Chairman of the Scientific Supervisory Board of the National Institute of Public Health and Environment, chairman of the Supervisory Board of the Biomedical Primate Research Centre, member of the Supervisory Board of the Royal Tropical Institute, co-chair of the Ghanaian-Dutch Health research programme and chairman of the Medical Committee Netherlands-Vietnam. Joost Ruitenberg is honorary member of the Dutch Health Council, member of the Royal Netherlands Academy of Arts and Sciences. He authored more than 500 publications in national and international peer reviewed scientific journals. He is supervisor of more than 35 PhD studies.
Tobias Rinke de Wit - Secretary
Professor Tobias Rinke de Wit (PhD) is a molecular biologist and public health specialist who is Director Research of the PharmAccess Group. Tobias supervises operational research in the context of various PharmAccess programs, in particular with respect to healthcare quality, financing and mobile-health technologies. Tobias holds a chair at the University of Amsterdam, Department of Global Health and Amsterdam Institute for Global Health and Development leading a team of 10 PhD and Master students. In the 1990’s Tobias was Laboratory Director of the Ethio-Netherlands AIDS Research Project. He served as Associate Professor at the University of Addis Ababa. In his current position as Principal Investigator at the Department of Global Health of the Academic Medical Center, Tobias supports the development of connected biomedical technology for improved quality of healthcare delivery in Africa. Emphasis of his work on HIV drug resistance, leading the Pan-African Studies to Evaluate Resistance. Tobias has published over 175 articles in peer-reviewed journals and is serving in the Scientific Advisory Board of the Amsterdam Health & Technology Institute and the Board of MondialDx, Amsterdam.
Femke Markus - Treasurer
Associate Partner at Spring Associates since 2006, a strategy consulting firm focusing on developing growth strategies with a strong focus on going beyond delivering the strategic plan and making strategy happen. Over the past years Femke has specialised in business development in the Pharma, Medtech and NGO sector. Femke combines her corporate business development expertise with experience in the not-for-profit public health arena and continuously seek for opportunities to establish new initiatives that contribute to a better society, especially in low- and middle- income countries. Example project assignments in this area: Interim Director Business Development & Partnerships of the Max Foundation, providing health programs to prevent child mortality in Asia (2016-current), Business development of OneDx, an open innovation hub for rapid diagnostics (2014-2015), Strategic advice Merck KGaA on their Access to Medicine strategy (2011-2015), Chair of the board of the Max Foundation, (2011-2015). Femke has a MSc in Industrial Design at the Technical University of Delft.
Donald Kalff - Founder
After receiving his PhD degree from the Wharton School of the University of Pennsylvania Donald Kalff spent most of his professional life as manager of Royal Dutch Shell and as member of the Executive Committee of KLM, Royal Dutch Airlines. He is the author of two books and numerous articles on the governance and management of large enterprises and on the competiveness of Europe. His latest book: "The Liberial Enterprise, value creation for society" will appear in the course of 2017. He is the co-founder of AIMM Therapeutics, a biotech company, and the founder of MondialDx. He recently co-founed Tillia Pharma a company that seeks to bring the diagnosis and treatment of tropical skin diseases to a higher level.
Professor Paul R. Klatser is currently Strategic Lead Preventive Biomarkers at Janssen Prevention Center of J&J in Leiden, The Netherlands, with Prof. Jaap Goudsmit as Global Director of the Center. Before he was heading the Royal Tropical Institute’s (KIT) department of Biomedical Research in Amsterdam with more than 40 professionals. Dr. Klatser has a background in biochemistry/immunology and was actively involved in tuberculosis research and diagnostic product development also together with private companies; he supervises several PhD students. He regularly advises multi-lateral organizations such as WHO on diagnostic issues related to infectious diseases and on laboratory quality management. He is board member of various editorial committees and organizations, both national and international, and has published over 125 papers in international peer-reviewed journals and several book chapters. He is Professor in Development and Evaluation of Diagnostic Tests in Developing Countries at the University of Amsterdam and Professor Extraordinary in Biomedical Research for Development at the Free University of Amsterdam.